Seroatlas · Human Serome Atlas

SUCLA2

Succinate--CoA ligase [ADP-forming] subunit beta, mitochondrial

Also known as: LINC00444, SUCB1_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q9P2R7
Gene
SUCLA2
Ensembl
ENSG00000136143
Chromosome
13
Canonical length
463 aa
Protein class
Citric acid cycle related proteins, Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Plasma proteins, Potential drug targets, Predicted intracellular proteins
Subcellular location
Mitochondria

OverviewNCBI Gene

Succinyl-CoA synthetase (SCS) is a mitochondrial matrix enzyme that acts as a heterodimer, being composed of an invariant alpha subunit and a substrate-specific beta subunit. The protein encoded by this gene is an ATP-specific SCS beta subunit that dimerizes with the SCS alpha subunit to form SCS-A, an essential component of the tricarboxylic acid cycle. SCS-A hydrolyzes ATP to convert succinate to succinyl-CoA. Defects in this gene are a cause of myopathic mitochondrial DNA depletion syndrome. A pseudogene of this gene has been found on chromosome 6. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

463 residues, UniProt reviewed canonical sequence.

>Q9P2R7|SUCLA2
     1  MAASMFYGRL VAVATLRNHR PRTAQRAAAQ VLGSSGLFNN HGLQVQQQQQ RNLSLHEYMS
    61  MELLQEAGVS VPKGYVAKSP DEAYAIAKKL GSKDVVIKAQ VLAGGRGKGT FESGLKGGVK
   121  IVFSPEEAKA VSSQMIGKKL FTKQTGEKGR ICNQVLVCER KYPRREYYFA ITMERSFQGP
   181  VLIGSSHGGV NIEDVAAESP EAIIKEPIDI EEGIKKEQAL QLAQKMGFPP NIVESAAENM
   241  VKLYSLFLKY DATMIEINPM VEDSDGAVLC MDAKINFDSN SAYRQKKIFD LQDWTQEDER
   301  DKDAAKANLN YIGLDGNIGC LVNGAGLAMA TMDIIKLHGG TPANFLDVGG GATVHQVTEA
   361  FKLITSDKKV LAILVNIFGG IMRCDVIAQG IVMAVKDLEI KIPVVVRLQG TRVDDAKALI
   421  ADSGLKILAC DDLDEAARMV VKLSEIVTLA KQAHVDVKFQ LPI

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against SUCLA2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Intracellular
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.3
Highest tissue expression
254 nTPM

Expression across tissuesHPA

Tissue

  • tongue: 254 nTPM
  • skeletal muscle: 217 nTPM
  • heart muscle: 94 nTPM
  • kidney: 72 nTPM
  • parathyroid gland: 67 nTPM
  • duodenum: 55 nTPM

Single-cell type

  • late spermatids: 486 nCPM
  • early spermatids: 424 nCPM
  • endometrial luminal cells: 180 nCPM
  • adipocytes: 165 nCPM
  • myonuclei: 159 nCPM
  • late primary spermatocytes: 156 nCPM

Immune cell

  • myeloid DC: 63 nTPM
  • intermediate monocyte: 54 nTPM
  • NK-cell: 52 nTPM
  • classical monocyte: 50 nTPM
  • plasmacytoid DC: 50 nTPM
  • naive CD4 T-cell: 48 nTPM

Brain region

  • hypothalamus: 72 nTPM
  • cerebellum: 69 nTPM
  • cerebral cortex: 69 nTPM
  • white matter: 64 nTPM
  • choroid plexus: 63 nTPM
  • thalamus: 63 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about SUCLA2.

Disease | AllUniProt

Conditions SUCLA2 is implicated in, by any mechanism.

Disease | GeneticClinVar

34 pathogenic / likely-pathogenic of 493 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.63
gnomAD pLI
0
gnomAD missense Z
1.02
DepMap mean gene effect
-0.18
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of SUCLA2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads SUCLA2 as an antibody target. Whether an autoantibody or antibody against SUCLA2 could matter depends on whether native SUCLA2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

SUCLA2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label SUCLA2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/SUCLA2. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

Loading the interactive Seroatlas protein explorer...